For instance, SCFAs can inhibit inflammatory responses by binding to G protein-coupled receptors (such as GPR41, GPR43, and GPR109A), thereby slowing down the progression of pulmonary fibrosis to a certain extent (Sivaprakasam et al., 2016). Here, FFAR3 is linked to pulmonary fibrosis.